[1] Tsochatzis EA,Bosch J,Burroughs AK.Liver cirrhosis. Lancet,2014,383(9930):1749-1761.
[2] Perz JF,Armstrong GL,Farrington LA,et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol,2006,45(4):529-538.
[3] Fouad YM.Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Trop Gastroenterol,2013,34(2):58-67.
[4] Louie KS,Micallef JM,Pimenta JM,et al:Prevalence of thrombocytopenia among patients with chronic hepatitis C:a systematic review. J Viral Hepat,2011,18(1):1-7.
[5] Taniguchi H,Iwasaki Y,Fujiwara A,et al.Long-term monitoring of platelet count,as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol,2006,21(1 Pt 2):281-287.
[6] 曾小琪,黄式文,冯桂玲,等.天门冬氨酸氨基转移酶/血小板比值在HBV感染相关疾病中的应用. 检验医学与临床,2014,6(11):1568-1569.
[7] Qamar AA,Grace ND,Groszmann RJ,et al.Portal hypertension collaborative group incidence,prevalence,and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol,2009,7(6):689-695.
[8] Kaushansky K.Thrombopoietin. N Engl J Med,1998,339(11):746-754.
[9] Lee GR,Foerster J,Lukens J,et al. Wintrobe’s clinical hematology. 10th ed. Baltimore:Williams & Wilkins,1998,615-683,1557-1632.
[10] George JN.Platelets. Lancet,2000,355(9214):1531-1539.
[11] Kuter DJ,Begley CG.Recombinant human thrombopoietin:Basic biology and evaluation of clinical studies. Blood,2002,100(10):3457-3469.
[12] Drews RE.Critical issues in hematology:anemia,thrombocytopenia,coagulopathy,and blood product transfusion in critically ill patients. Clin Chest Med,2003,24(4):607-622.
[13] Young NS.Flaviviruses and bone marrow failure. JAMA,1990,263(22):3065-3068.
[14] Mayo MJ.Extrahepatic manifestations of hepatitis C infection. Am J Med Sci,2003,325(3):135-148.
[15] Martin TG,Somberg KA,Meng YG,et al.Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med,1997,127(4):285-288.
[16] Peck-Radosavljevic M,Wichlas M,Zacherl J,et al.Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood,2000,95(3):795-801.
[17] Yanaga K,Tzakis AG,Shimada M,et al.Reversal of hypersplenism following orthotopic liver transplantation. Ann Surg,1989,210(2):180-183.
[18] Adinolfi LE,Giordano MG,Andreana A,et al.Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Brit J Haematol,2001,113(3):590-595.
[19] Giannini E,Borro P,Botta F,et al.Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol,2002 37(5):572-577.
[20] Murawaki Y,Koda M,Okamoto K,et al.Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol,2001,16(77):777-781.
[21] Pohl A,Behling C,Oliver D,et al.Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol,2001,96(11):3142-3146.
[22] van der Meer AJ,Veldt BJ,Feld JJ,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA,2012,308(24):2584-2593.
[23] Fattovich G,Giustina G,Degos F et al. Morbidity and mortality incompensated cirrhosis type C:a retrospective follow-up study of 384 patients. Gastroenterology,1997,112(2):463-472.
[24] Cardoso AC,Moucari R,Figueiredo-Mendes C,et al.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma:incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol,2010,52(5):652-657.
[25] Morgan TR,Ghany MG,Kim HY,et al.Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology,2010,52(3):833-844.
[26] Teshale E,Lu M,Rupp LB,et al.APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B:the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat,2014,21(12):917-920.
[27] Castera L,Winnock M,Pambrun E,et al.Comparison of transient elastography(FibroScan),FibroTest,APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients:ANRS CO13HEPAVIH and FIBROSTIC collaboration. HIV Med,2014,15(1):30-39.
[28] Alboraie M,Khairy M,Elsharkawy M,et al. Value of Egy-score in diagnosis of significant,advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index,FIB4 and Forns’index in chronic hepatitis C virus. Hepatol Res,2015,45(5)560-570.
[29] Takaki S,Kawakami Y,Miyaki D,et al.Non-invasive liver fibrosis score calculatedby combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. Hepatol Res,2014,44(3):280-287.
[30] Coverdale SA,Samarasinghe DA,Lin R,et al.Changes in antipyrine clearance and platelet count,but not conventional liver tests,correlate with fibrotic change in chronic hepatitis C:value for predicting fibrotic progression. Am J Gastroenterol,2003,98(6):1384-1390.
[31] Omata M,Kanda T,Wei L,et al.APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int,2016,10(5):702-726.
[32] Hermos JA,Quach L,Gagnon DR,et al.Incident severe thrombocytopeniain veterans treated with pegylated interferon plus ribavirin forchronic hepatitis C infection. Pharmacoepidemiol Drug Saf,2014,23(5):480-488.
[33] Lin KH,Hsu PI,Yu HC,et al.Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. BMC Gastroenterol,2012,12:7.
[34] Dienstag JL,McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology,2006,130(1):231-264.
[35] Wang H,Innes H,Hutchinson SJ,et al.The prevalence and impact of thrombocytopenia,anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy:evidence from a large 'real-world' cohort. Eur J Gastroenterol Hepatol,2016,28(4):398-404.
[36] Dahal S,Upadhyay S,Banjade R,et al.Thrombocytopenia in patients with chronic hepatitis C Virus infection. Mediterr J Hematol Infect Dis,2017,9(1):e2017-19.
[37] Koh C,Heller T,Haynes-Williams V,et al.Long term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy long term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Therapeut,2013,37(9):887-894.
[38] Kurokawa T,Zheng YW,Ohkohchi N.Novel functions of platelets in the liver. J Gastroenterol Hepatol,2016,31(4):745-751.
[39] Murata S,Maruyama T,Nowatari T,et al.Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis. Int J Mol Sci,2014,15(4):5412-5425.
[40] Nakajima H,Takagi H,Yamazaki Y,et al.Immune thrombocytopenic purpura in patients with hepatitis C virus infection. Hepatogastroenterology,2005,52(64):1197-200.
[41] Pawlotsky JM,Bouvier M,Fromont P,et al.Hapatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol,1995,23(6):635-639.
[42] Ichimata S,Kobayashi M,Honda K,et al.Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection. World Gastroenterol,2017,23(35):6540-6545.
[43] Feld JJ,Jacobson IM,Hezode C,et al.Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5,and 6 infection. N Engl J Med,2015,373(27):2599-2607.
[44] Foster GR,Afdhal N,Roberts SK,et al.Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med,2015,373(27):2608-2617.
[45] Forns X,Poordad F,Pedrosa M,et al.Ombitasvir/paritaprevir/r,dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. Liver Int,2015,35(11):2358-2362. |
